Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto)

X
Trial Profile

A randomized phase III trial comparing nanoparticle-based paclitaxel with solvent-based paclitaxel as part of neoadjuvant chemotherapy for patients with early breast cancer (GeparSepto)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Paclitaxel (Primary) ; Cyclophosphamide; Epirubicin; Pertuzumab; Trastuzumab
  • Indications Carcinoma; Early breast cancer; HER2 positive breast cancer; Triple negative breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms G7; GeparSepto
  • Most Recent Events

    • 11 Jul 2023 Results (n=279) assessing the prognostic and predictive potential of CAV1/2 expression for early-stage HER2-negative breast cancer patients receiving neoadjuvant paclitaxel-based chemotherapy regimens, published in the Clinical Cancer Research.
    • 04 Apr 2023 Results (n=279 of HER2 negative BC patients) assessing immune-cell activity of BC tumors by expression-based analysis to determine if it is prognostic and/or predictive of response to neoadjuvant paclitaxel-based therapy published in the Clinical Cancer Research
    • 13 May 2019 Status changed to completed as per results published in the Journal of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top